Compile Data Set for Download or QSAR
Report error Found 184 Enz. Inhib. hit(s) with all data for entry = 2943
TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385597(US10287292, Compound 1.001 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385599(US10287292, Compound 1.003 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385602(US10287292, Compound 1.006 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385606(US10287292, Compound 1.009 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385610(US10287292, Compound 1.012 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385611(US10287292, Compound 1.013 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385614(US10287292, Compound 1.014 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385617(US10287292, Compound 1.015 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385618(US10287292, Compound 1.016 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385619(US10287292, Compound 1.017 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385623(US10287292, Compound 1.019 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385625(US10287292, Compound 1.020 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385626(US10287292, Compound 1.021 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385627(US10287292, Compound 1.022 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385629(US10287292, Compound 1.023 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385630(US10287292, Compound 1.024 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385631(US10287292, Compound 1.025 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385633(US10287292, Compound 1.026 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385699(US10287292, Compound 1.028 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385717(US10287292, Compound 1.029 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385738(US10287292, Compound 1.030 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385743(US10287292, Compound 1.031 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385805(US10287292, Compound 1.032 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385818(US10287292, Compound 1.034)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385819(US10287292, Compound 1.035 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385823(US10287292, Compound 1.036 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385859(US10287292, Compound 1.037 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385860(US10287292, Compound 1.038 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385861(US10287292, Compound 1.039 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385862(US10287292, Compound 1.040 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385863(US10287292, Compound 1.041 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385864(US10287292, Compound 1.042 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385866(US10287292, Compound 1.044 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385867(US10287292, Compound 1.045 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385868(US10287292, Compound 1.046 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385870(US10287292, Compound 1.048 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385871(US10287292, Compound 1.049)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385872(US10287292, Compound 1.050 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385873(US10287292, Compound 1.051 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385874(US10287292, Compound 1.052 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385875(US10287292, Compound 1.053 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385876(US10287292, Compound 1.054)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385877(US10287292, Compound 1.055 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385879(US10287292, Compound 1.057 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385880(US10287292, Compound 1.058 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385881(US10287292, Compound 1.059 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385882(US10287292, Compound 1.060 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385884(US10287292, Compound 1.062)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385886(US10287292, Compound 1.064 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

TargetAtypical chemokine receptor 3(Human)
Chemocentryx

US Patent
LigandPNGBDBM385887(US10287292, Compound 1.065 | US11059825, Compound ...)
Affinity DataIC50: 500nMAssay Description:In order to more properly assess the binding efficacy of the compounds, radioligand binding assays were carried out in the presence of 100% human ser...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/27/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 184 total ) | Next | Last >>
Jump to: